What antibiotic is effective for treating this infection?

From the Guidelines

The most effective antibiotic for treating the infection cannot be determined without knowing the type of infection, its severity, and the causative pathogen. Given the provided antibiotic susceptibility results, it appears that the pathogen is susceptible to several antibiotics, including AMOX/CLAVULANATE, AMP/SULBACTAM, CEFEPIME, CEFTAZIDIME, CEFTRIAXONE, CIPROFLOXACIN, GENTAMICIN, IMIPENEM, LEVOFLOXACIN, MEROPENEM, NITROFURANTOIN, and PIP/TAZOBACTAM. However, the choice of antibiotic should be guided by the severity of the infection, the site of infection, and local resistance patterns, as well as patient-specific factors such as allergies and kidney or liver function 1. For example, in the case of hospital-acquired pneumonia, the guidelines recommend assessing the risk for MDR pathogens and mortality, and choosing an antibiotic based on this assessment, such as ertapenem, ceftriaxone, cefotaxime, moxifloxacin, or levofloxacin for low-risk patients, and a single Gram-negative agent or dual Gram-pseudomonal coverage for high-risk patients 1. Similarly, for diabetic foot infections, the guidelines recommend choosing an antibiotic based on the severity of the infection and the likely causative pathogens, such as dicloxacillin, clindamycin, or levofloxacin for mild infections, and ertapenem, piperacillin/tazobactam, or tigecycline for moderate to severe infections 1. In the case of infections caused by multidrug-resistant bacteria, such as KPC-producing CRE, the guidelines recommend using novel β-lactam agents such as ceftazidime/avibactam or meropenem/vaborbactam as first-line treatment options 1. Ultimately, the choice of antibiotic should be individualized based on the specific clinical scenario and guided by a healthcare provider who can evaluate the patient and consider local resistance patterns. Some key points to consider when choosing an antibiotic include:

• The type and severity of the infection
• The likely causative pathogens
• Local resistance patterns
• Patient-specific factors such as allergies and kidney or liver function
• The need for broad-spectrum coverage versus targeted therapy
• The potential for antibiotic resistance and the need for stewardship. It is essential to consult with a healthcare provider to determine the best course of treatment for a specific infection.

From the FDA Drug Label

Gentamicin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative) Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns)

The effective antibiotics for treating this infection are:

• Gentamicin: effective against Pseudomonas aeruginosa, Proteus species, Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species.
• Other antibiotics may be effective as well, but the provided information only directly supports the use of Gentamicin 2.

From the Research

Effective Antibiotics for Treating Infections

Based on the provided information, the following antibiotics are effective for treating infections:

• AMOX/CLAVULANATE: sensitive at <=2 μg/mL
• AMP/SULBACTAM: sensitive at <=2 μg/mL
• CEFEPIME: sensitive at <=0.12 μg/mL 3, 4, 5, 6, 7
• CEFTAZIDIME: sensitive at <=1 μg/mL 3, 4, 5, 6
• CEFTRIAXONE: sensitive at <=0.25 μg/mL 6
• CIPROFLOXACIN: sensitive at <=0.06 μg/mL 4, 6, 7
• GENTAMICIN: sensitive at <=1 μg/mL 7
• IMIPENEM: sensitive at <=0.25 μg/mL 3, 4, 6
• LEVOFLOXACIN: sensitive at <=0.12 μg/mL 4, 6, 7
• MEROPENEM: sensitive at <=0.25 μg/mL 3, 6
• PIP/TAZOBACTAM: sensitive at <=4 μg/mL 4, 6, 7

Considerations for Antibiotic Use

When choosing an antibiotic, consider the following:

• The type of infection and the causative pathogen
• The antibiotic's spectrum of activity and potential for resistance
• The patient's medical history and potential allergies or interactions
• The results of antimicrobial susceptibility testing, such as those reported in studies 3, 4, 5, 6, 7